More on Bio + Health
THE LEADING EDGE IN

Therapeutics

Next Generation
Modalities

Diagnostics
& Precision Medicine

High Throughput
Research

Engineering
Clinical Development

Beyond
Medicine

AI + Bio

It’s Time to
Build in Bio

Our ability to engineer biology is fundamentally transforming how we diagnose, treat, and manage disease. Modern tools like CRISPR and gene circuitry enable us to program biology with greater precision and sophistication. The explosion of “programmable medicines” (in the form of genes, cells, microbes, and even mobile apps and software that can improve our health itself) are today leading us closer than ever before to that holy grail of medicine, the cure.

Because these new medicines are engineered systems and programmable in nature, drug discovery and development is becoming an engineered, iterative process. We can now move from designing a molecule for one specific target to designing a platform on which many future medicines can be built. And the modular aspect of these medicines mean that new applications will be easier to build, reusing and repurposing common components like Lego blocks: Once we learn how to deliver a gene to a specific cell in a given disease, it’s significantly more likely we will be able to deliver a different gene to a different cell for another disease.

Biology is incredibly complex —maybe even beyond the ability of the human mind to fully comprehend. AI-powered platforms have the potential to connect dots that have before looked like noise; to generate new discoveries; even to change the nature of discovery itself. This will drive both new therapies and next-generation diagnostics that give us the ability to detect diseases like cancer earlier and earlier, perhaps even stopping disease before it begins..

The
Leading
Edge in:

AI + Bio

AI is radically transforming the ways new medicines are discovered and developed, and delivering important innovations in the tools and platforms to drive efficient drug development.

Next Generation Modalities

Platform companies advancing the discovery and development of next generation of RNA medicines and vaccines, biologics and cell and gene therapies

Precision Healthcare

Delivering personalized diagnostics and therapeutics that enable more precise and personalized treatment pathways.

High Throughput Research

Tools and platforms that power charge research capabilities through lower cost and high throughput

Clinical Development

Reimaging new ways to optimize drug design, development and commercialization.

Bio Eats World
(Beyond Medicine)

Plant-based and organic foods and natural coatings to transform the food supply chain

Therapeutics

Platform companies developing the next generation of small molecule therapeutics to treat a wide range of chronic and acute diseases.

Bio Builders

stage at initial investment
SPAC: EQRX
IPO: ERAS
Acquired By: Invitae
SPAC: NAUT
Acquired By: Ginkgo Bioworks
SPAC: RGTI
Acquired By: Kite Pharma
Print this list

Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. Exits include current and former a16z portfolio companies which have been acquired as well as companies which have undergone an initial public offering or direct public offering of shares. Certain publicly traded companies on this list may still be held in Andreessen Horowitz funds. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Excluded from this list are investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets. Further, the list of investments is updated monthly and as such may not reflect most recent a16z investments. Past results of Andreessen Horowitz’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results.

Themes in Bio

FEATURED ARTICLE

Doing More
with Moore

Science-native SaaS tools are modernizing how medicines are discovered, developed, and distributed.
PODCAST

Raising Health

Our top-ranked podcast exploring the real challenges and enormous opportunities facing entrepreneurs who are building the future of health.
THESIS AREA

Building in Bio

A new generation of founders is building a new generation of bio companies.
BIO EATS WORLD

Journal Club: Remodeling oncogenic transcriptomes

Unexpected results and translational implications from a recent paper, in one of our Journal Club podcast episodes.
THESIS AREA

AI in Bio + Health

A universe of new therapies, next-gen diagnostics, and provider tools is on the horizon.
BIO EATS WORLD

Advancing
the Field of Immunotherapies

Immuno-oncology and current challenges in drug targeting, explained.

THESIS AREA

Therapeutics

It’s not just biology that’s evolving. Our therapeutics are too.
BIO EATS WORLD

AI and Actionable Drug Insights with Daphne Koller

Hear about how AI can enable new models of discovery in biology, in this episode of Bio Eats World.
FEATURED ARTICLE

Platform-Partnership Fit for Bio Startups

The goose can finally lay the proverbial golden eggs…but because the platform is so broadly applicable, it becomes even more difficult to know where to start.

  • The Power of Drug Discovery with Philip Tagari New

    Vijay Pande, Philip Tagari, Kris Tatiossian, and Olivia Webb

    Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.

  • AI-Enabled Continuity of Care with Ed and Todd Park

    Vijay Pande, Ed Park, Todd Park, Steph Smith, Kris Tatiossian, and Olivia Webb

    Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.

  • Grand Challenges in Healthcare AI with Vijay Pande and Julie Yoo

    Vijay Pande, Julie Yoo, Kris Tatiossian, and Olivia Webb

    Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.

  • Behind the Buy: Payors and Providers on AI Adoption

    Julie Yoo, Jay Rughani, Kris Tatiossian, and Olivia Webb

    This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.

  • Biotech Revolution with Software Engineering Daily

    Sean Falconer, Vijay Pande, Kris Tatiossian, and Olivia Webb

    Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.

Load More
AVAILABLE NOW ON SPOTIFY

Raising
Health™

Our top-ranked podcast exploring the real challenges and enormous opportunities facing entrepreneurs who are building the future of health.

listen now
go to top